The extended Metabolic Signalling Set covers incretin and mitochondrial compounds for experiments on insulin signalling, glucose handling and lipid metabolism. Tirzepatide, CJC-1295 No DAC, Ipamorelin, 5-Amino-1MQ and MOTS-C are supplied together at a lower cost than ordering separately.
- Tirzepatide 10mg vial, a dual agonist at the GLP-1 and GIP receptors
- CJC-1295 No DAC 10mg vial, a tetra-substituted analogue of GHRH (1-29)
- Ipamorelin 10mg vial, a selective pentapeptide agonist at the ghrelin receptor GHS-R1a
- 5-Amino-1MQ 10mg vial, a small molecule inhibitor of the enzyme NNMT
- MOTS-C 10mg vial, a sixteen amino acid peptide encoded in mitochondrial DNA
Metabolic Signalling Set (Extended) research applications
- HTRF or GloSensor cAMP assays in cell lines expressing GIPR or GLP-1R separately, the Tirzepatide readout
- Recombinant NNMT assays by LC-MS (5-Amino-1MQ) and glucose uptake with 2-deoxyglucose or 2-NBDG in myotubes (MOTS-C)
- cAMP in pituitary somatotrophs (CJC-1295 No DAC) and calcium mobilisation in GHS-R1a lines (Ipamorelin)
Research profiles: Tirzepatide, CJC-1295, Ipamorelin, 5-Amino-1MQ and MOTS-C
What is tested in this set
This set contains five products, each supplied in its own vial and each tested on its own. The table lists the published result for every component.
| Component | Purity | Laboratory | Analysed | Certificate |
|---|---|---|---|---|
| Tirzepatide | 99.74% | Janoshik Analytical | 24 Sep 2026 | View |
| CJC-1295 No DAC | 99.46% | Janoshik Analytical | 9 Jul 2026 | View |
| Ipamorelin | 99.71% | Janoshik Analytical | 9 Jul 2026 | View |
| 5-Amino-1MQ | 99.41% | Janoshik Analytical | 11 Nov 2025 | View |
| MOTS-C | 99.28% | Janoshik Analytical | 24 Sep 2026 | View |










